REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
50,000 sale just took buy price to 11.8p
never thought we would pull back again
:(
ir@midatechpharma.com
Every one needs to push for news as promised 3 months ago in the you tube vidios .
Last 2 years it has completely collapsed it's about time to Chase him and ask him what the **** is he doing about the share price. Eny one have an email address ?
Down to $0.60 now - I hope Stamp has something for the markets in the morning
It can't be in Janssen's interest to see MTPH run out of cash, given their ongoing collaboration/research programs + I don't think they would have agreed to carry on with MTPH if they thought MTPH wouldn't be around to finish the development work... Hoping if push comes to shove Janssen will step in, as again would not be in their interest for another large pharma to take over MTPH and control of all operations... Of course this all depends on how much value Janssen are actually putting on their ongoing Q-sphera developments... fingers crossed quite a bit, if MTPH deliver..
Janssen have played a blinder. Midatech are blind
When Jannsen extended it would have been a good opportunity to say ... money!!
Jansenn have extended to the point where Midatech will be wanting more money , so will be in a strong negotiating position now if no other deals are done
Out of hours $0.65 - this is dire and Stamp needs to wake up to the possibility of NASDAQ delisting and the snowball effect of no concrete news.
Forget the misty eyed glory of ‘going it alone’ on Q-Sphera - partner up, get Janssen onboard fiscally and show the market that the threat of further dilution has gone and more than just Midatech BOD believe in their goals and objectives
This will not change on goodwill alone. AIM is sentiment driven
Would be nice if some targets had been met , small number I know but ???
Frustrating on low volume
As chique says, plenty of months yet - at least 7 imho - to go before they even have to consider starting discussions re 2023 funding.. and a lot can happen in 7 plus months.... especially with the Janssen collabations..
Also, i'm reasonably confident that they'd get anther few million - at least - raise away here around the end of this year, if needs be.. granted potentially a price as low as in the 10 to 15p area even, alas..
That said, I've tweaked my holding strategy somewhat here for 2022 : every quarter of 2022 I'm selling down 20% of my holding here .. unless /until meaninghful - revenue related - news drops....as ever, I'm also very open to range trading too off the back of any meaningful news drop(s) if there were to be any, of course. ( sure I'd lose a fair few k from continuing to do this, but I'm, fortunately, way up from range trading the spikes and trough over the years here and so fine with giving a bit of the houses money back )
PS: I change my strategy as I believe the current CEO has little 'hard core marketing' orientation about him, versus previous management.. and so spikes and fall backs are far less likely here in 2022 versus previous years.. ( and so range trading oppportunities will be diminished markedly here in 2022 imho..
Good thing is they don't need to commit to fundraise or partnership till late on in the year by when there may well be a breakthrough
They mention assett partnering which could be beneficial as it's a sort of half way house between selling company ( with all IP ) and ensuring further cashflow from an individual partnered assett , possibly Jansenn an option on this.
Time to make a name for themselves
Todays RNS main takeaway - cash till first quarter 2023
2p above the last placing!
Don't think we would go to dizzy heights but around the 30p mark for the patents and IP could be achievable , which from this SP is a good return
what would be paid?! the sp is at rock bottom - any larger company could swallow us up with little more than their stationary budget. very frustrating at the mo
I think we could do well from here if the is a merger with a larger company
they must have known this was coming - as you say, they need to get their finger out - surely only a matter of time now...
time they got a move on with discussions
Been traded since the bell…
... at last!